Galecto, Inc. Board of Directors

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Dr. Hans T. Schambye M.D., Ph.D.

Dr. Hans T. Schambye M.D., Ph.D.

Co-Founder, President, CEO & Director

Mr. Garrett Winslow Esq.

Mr. Garrett Winslow Esq.

Senior VP, General Counsel & Corporate Secretary

Ms. Lori C. Firmani

Ms. Lori C. Firmani

Interim Chief Financial Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.